Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer
The purpose of this study was to compare efficacy and safety of a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) and gemcitabine-cisplatin as first-line therapy in patients with pancreatic cancer. Pancreaticobiliary cancer patients w...
Gespeichert in:
| Veröffentlicht in: | TURKISH JOURNAL OF MEDICAL SCIENCES 2021-08, Vol.51 (4), p.1727-1732 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1732 |
|---|---|
| container_issue | 4 |
| container_start_page | 1727 |
| container_title | TURKISH JOURNAL OF MEDICAL SCIENCES |
| container_volume | 51 |
| creator | Kayahan, Neslihan Karaca, Mustafa Satış, Hasan Yapar, Dilek Özet, Ahmet |
| description | The purpose of this study was to compare efficacy and safety of a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) and gemcitabine-cisplatin as first-line therapy in patients with pancreatic cancer.
Pancreaticobiliary cancer patients who had Eastern Cooperative Oncology Group performance status score of 0 or 1 (on a scale of 0 to 5, with higher scores indicating greater severity of illness) were evaluated to receive folfirinox or gemcitabine plus cisplatin. The primary endpoints were progression-free and overall survival time. Safety analysis was also evaluated as secondary measures.
There were 32 patients in the folfirinox group and 36 patients in the gemcitabine-cisplatin group. The median overall survival was 18.1 months (7.5–28.7) in the folfirinox group as compared with 9.7 months (6.5–13) in the gemcitabine-cisplatin group (p = 0.009). Median progression-free survival was 16.2 months (9–23.4) in the folfirinox group and 6.9 months (6.1–7.6) in the gemcitabine- cisplatin group (p = 0.001).
Folfirinox is an option for the first-line treatment of patients with pancreatic cancer and good performance status. |
| doi_str_mv | 10.3906/sag-2009-115 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8569782</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>33315355</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-a87f9e272fb677649e59481a35a9ea6f23b1eace3910151557c0086722a08edb3</originalsourceid><addsrcrecordid>eNpVkE1LAzEQhoMoVqs3z5IfYDQfTXZzEaRYFQpe9Bxm02wb2d0sybbYf29KtdTTfL3zzvAgdMPovdBUPSRYEk6pJozJE3TBBBVEMSVPj_IRukzpi1IuJlKfo5EQgkkh5QVKs9DUPvoufOONi2md8NK11g9Q-c4R61PfwOA7bEObOzkNHYaE804aSJM1eFi5CP0WZ9EQHQyt6wYcatxDZ3e1t6HyjYe4xTa3XLxCZzU0yV3_xjH6nD1_TF_J_P3lbfo0J1aUk4FAWdTa8YLXlSoKNdFO6knJQEjQDlTNRcUcWCc0o0wyKQtLaakKzoGWblGJMXrc-_brqnULm_-K0Jg--jY_YwJ483_S-ZVZho0ppdJFybPB3d7AxpBSdPVhl1Gzg28yfLODbzL8LL89vncQ_9EWP_-ChFQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer</title><source>MEDLINE</source><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>TÜBİTAK Scientific Journals</source><creator>Kayahan, Neslihan ; Karaca, Mustafa ; Satış, Hasan ; Yapar, Dilek ; Özet, Ahmet</creator><creatorcontrib>Kayahan, Neslihan ; Karaca, Mustafa ; Satış, Hasan ; Yapar, Dilek ; Özet, Ahmet</creatorcontrib><description>The purpose of this study was to compare efficacy and safety of a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) and gemcitabine-cisplatin as first-line therapy in patients with pancreatic cancer.
Pancreaticobiliary cancer patients who had Eastern Cooperative Oncology Group performance status score of 0 or 1 (on a scale of 0 to 5, with higher scores indicating greater severity of illness) were evaluated to receive folfirinox or gemcitabine plus cisplatin. The primary endpoints were progression-free and overall survival time. Safety analysis was also evaluated as secondary measures.
There were 32 patients in the folfirinox group and 36 patients in the gemcitabine-cisplatin group. The median overall survival was 18.1 months (7.5–28.7) in the folfirinox group as compared with 9.7 months (6.5–13) in the gemcitabine-cisplatin group (p = 0.009). Median progression-free survival was 16.2 months (9–23.4) in the folfirinox group and 6.9 months (6.1–7.6) in the gemcitabine- cisplatin group (p = 0.001).
Folfirinox is an option for the first-line treatment of patients with pancreatic cancer and good performance status.</description><identifier>ISSN: 1303-6165</identifier><identifier>ISSN: 1300-0144</identifier><identifier>EISSN: 1303-6165</identifier><identifier>DOI: 10.3906/sag-2009-115</identifier><identifier>PMID: 33315355</identifier><language>eng</language><publisher>Turkey: The Scientific and Technological Research Council of Turkey</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Cisplatin - adverse effects ; Cisplatin - therapeutic use ; Deoxycytidine - adverse effects ; Deoxycytidine - analogs & derivatives ; Deoxycytidine - therapeutic use ; Female ; Fluorouracil - adverse effects ; Fluorouracil - therapeutic use ; Gastrointestinal Neoplasms ; Gemcitabine ; Humans ; Irinotecan - adverse effects ; Irinotecan - therapeutic use ; Leucovorin - adverse effects ; Leucovorin - therapeutic use ; Male ; Middle Aged ; Oxaliplatin - adverse effects ; Oxaliplatin - therapeutic use ; Pancreatic Neoplasms ; Pancreatic Neoplasms - drug therapy ; Pancreatic Neoplasms - pathology ; Treatment Outcome</subject><ispartof>TURKISH JOURNAL OF MEDICAL SCIENCES, 2021-08, Vol.51 (4), p.1727-1732</ispartof><rights>This work is licensed under a Creative Commons Attribution 4.0 International License.</rights><rights>Copyright © 2021 The Author(s) 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-a87f9e272fb677649e59481a35a9ea6f23b1eace3910151557c0086722a08edb3</citedby><orcidid>0000-0002-7605-1301 ; 0000-0001-7656-1152 ; 0000-0001-8731-9636 ; 0000-0002-6802-7926 ; 0000-0002-3954-5273</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8569782/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8569782/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33315355$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kayahan, Neslihan</creatorcontrib><creatorcontrib>Karaca, Mustafa</creatorcontrib><creatorcontrib>Satış, Hasan</creatorcontrib><creatorcontrib>Yapar, Dilek</creatorcontrib><creatorcontrib>Özet, Ahmet</creatorcontrib><title>Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer</title><title>TURKISH JOURNAL OF MEDICAL SCIENCES</title><addtitle>Turk J Med Sci</addtitle><description>The purpose of this study was to compare efficacy and safety of a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) and gemcitabine-cisplatin as first-line therapy in patients with pancreatic cancer.
Pancreaticobiliary cancer patients who had Eastern Cooperative Oncology Group performance status score of 0 or 1 (on a scale of 0 to 5, with higher scores indicating greater severity of illness) were evaluated to receive folfirinox or gemcitabine plus cisplatin. The primary endpoints were progression-free and overall survival time. Safety analysis was also evaluated as secondary measures.
There were 32 patients in the folfirinox group and 36 patients in the gemcitabine-cisplatin group. The median overall survival was 18.1 months (7.5–28.7) in the folfirinox group as compared with 9.7 months (6.5–13) in the gemcitabine-cisplatin group (p = 0.009). Median progression-free survival was 16.2 months (9–23.4) in the folfirinox group and 6.9 months (6.1–7.6) in the gemcitabine- cisplatin group (p = 0.001).
Folfirinox is an option for the first-line treatment of patients with pancreatic cancer and good performance status.</description><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Cisplatin - adverse effects</subject><subject>Cisplatin - therapeutic use</subject><subject>Deoxycytidine - adverse effects</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Deoxycytidine - therapeutic use</subject><subject>Female</subject><subject>Fluorouracil - adverse effects</subject><subject>Fluorouracil - therapeutic use</subject><subject>Gastrointestinal Neoplasms</subject><subject>Gemcitabine</subject><subject>Humans</subject><subject>Irinotecan - adverse effects</subject><subject>Irinotecan - therapeutic use</subject><subject>Leucovorin - adverse effects</subject><subject>Leucovorin - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Oxaliplatin - adverse effects</subject><subject>Oxaliplatin - therapeutic use</subject><subject>Pancreatic Neoplasms</subject><subject>Pancreatic Neoplasms - drug therapy</subject><subject>Pancreatic Neoplasms - pathology</subject><subject>Treatment Outcome</subject><issn>1303-6165</issn><issn>1300-0144</issn><issn>1303-6165</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkE1LAzEQhoMoVqs3z5IfYDQfTXZzEaRYFQpe9Bxm02wb2d0sybbYf29KtdTTfL3zzvAgdMPovdBUPSRYEk6pJozJE3TBBBVEMSVPj_IRukzpi1IuJlKfo5EQgkkh5QVKs9DUPvoufOONi2md8NK11g9Q-c4R61PfwOA7bEObOzkNHYaE804aSJM1eFi5CP0WZ9EQHQyt6wYcatxDZ3e1t6HyjYe4xTa3XLxCZzU0yV3_xjH6nD1_TF_J_P3lbfo0J1aUk4FAWdTa8YLXlSoKNdFO6knJQEjQDlTNRcUcWCc0o0wyKQtLaakKzoGWblGJMXrc-_brqnULm_-K0Jg--jY_YwJ483_S-ZVZho0ppdJFybPB3d7AxpBSdPVhl1Gzg28yfLODbzL8LL89vncQ_9EWP_-ChFQ</recordid><startdate>20210830</startdate><enddate>20210830</enddate><creator>Kayahan, Neslihan</creator><creator>Karaca, Mustafa</creator><creator>Satış, Hasan</creator><creator>Yapar, Dilek</creator><creator>Özet, Ahmet</creator><general>The Scientific and Technological Research Council of Turkey</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7605-1301</orcidid><orcidid>https://orcid.org/0000-0001-7656-1152</orcidid><orcidid>https://orcid.org/0000-0001-8731-9636</orcidid><orcidid>https://orcid.org/0000-0002-6802-7926</orcidid><orcidid>https://orcid.org/0000-0002-3954-5273</orcidid></search><sort><creationdate>20210830</creationdate><title>Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer</title><author>Kayahan, Neslihan ; Karaca, Mustafa ; Satış, Hasan ; Yapar, Dilek ; Özet, Ahmet</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-a87f9e272fb677649e59481a35a9ea6f23b1eace3910151557c0086722a08edb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Cisplatin - adverse effects</topic><topic>Cisplatin - therapeutic use</topic><topic>Deoxycytidine - adverse effects</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Deoxycytidine - therapeutic use</topic><topic>Female</topic><topic>Fluorouracil - adverse effects</topic><topic>Fluorouracil - therapeutic use</topic><topic>Gastrointestinal Neoplasms</topic><topic>Gemcitabine</topic><topic>Humans</topic><topic>Irinotecan - adverse effects</topic><topic>Irinotecan - therapeutic use</topic><topic>Leucovorin - adverse effects</topic><topic>Leucovorin - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Oxaliplatin - adverse effects</topic><topic>Oxaliplatin - therapeutic use</topic><topic>Pancreatic Neoplasms</topic><topic>Pancreatic Neoplasms - drug therapy</topic><topic>Pancreatic Neoplasms - pathology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kayahan, Neslihan</creatorcontrib><creatorcontrib>Karaca, Mustafa</creatorcontrib><creatorcontrib>Satış, Hasan</creatorcontrib><creatorcontrib>Yapar, Dilek</creatorcontrib><creatorcontrib>Özet, Ahmet</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>TURKISH JOURNAL OF MEDICAL SCIENCES</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kayahan, Neslihan</au><au>Karaca, Mustafa</au><au>Satış, Hasan</au><au>Yapar, Dilek</au><au>Özet, Ahmet</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer</atitle><jtitle>TURKISH JOURNAL OF MEDICAL SCIENCES</jtitle><addtitle>Turk J Med Sci</addtitle><date>2021-08-30</date><risdate>2021</risdate><volume>51</volume><issue>4</issue><spage>1727</spage><epage>1732</epage><pages>1727-1732</pages><issn>1303-6165</issn><issn>1300-0144</issn><eissn>1303-6165</eissn><abstract>The purpose of this study was to compare efficacy and safety of a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) and gemcitabine-cisplatin as first-line therapy in patients with pancreatic cancer.
Pancreaticobiliary cancer patients who had Eastern Cooperative Oncology Group performance status score of 0 or 1 (on a scale of 0 to 5, with higher scores indicating greater severity of illness) were evaluated to receive folfirinox or gemcitabine plus cisplatin. The primary endpoints were progression-free and overall survival time. Safety analysis was also evaluated as secondary measures.
There were 32 patients in the folfirinox group and 36 patients in the gemcitabine-cisplatin group. The median overall survival was 18.1 months (7.5–28.7) in the folfirinox group as compared with 9.7 months (6.5–13) in the gemcitabine-cisplatin group (p = 0.009). Median progression-free survival was 16.2 months (9–23.4) in the folfirinox group and 6.9 months (6.1–7.6) in the gemcitabine- cisplatin group (p = 0.001).
Folfirinox is an option for the first-line treatment of patients with pancreatic cancer and good performance status.</abstract><cop>Turkey</cop><pub>The Scientific and Technological Research Council of Turkey</pub><pmid>33315355</pmid><doi>10.3906/sag-2009-115</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-7605-1301</orcidid><orcidid>https://orcid.org/0000-0001-7656-1152</orcidid><orcidid>https://orcid.org/0000-0001-8731-9636</orcidid><orcidid>https://orcid.org/0000-0002-6802-7926</orcidid><orcidid>https://orcid.org/0000-0002-3954-5273</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1303-6165 |
| ispartof | TURKISH JOURNAL OF MEDICAL SCIENCES, 2021-08, Vol.51 (4), p.1727-1732 |
| issn | 1303-6165 1300-0144 1303-6165 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8569782 |
| source | MEDLINE; PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; TÜBİTAK Scientific Journals |
| subjects | Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cisplatin - adverse effects Cisplatin - therapeutic use Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Female Fluorouracil - adverse effects Fluorouracil - therapeutic use Gastrointestinal Neoplasms Gemcitabine Humans Irinotecan - adverse effects Irinotecan - therapeutic use Leucovorin - adverse effects Leucovorin - therapeutic use Male Middle Aged Oxaliplatin - adverse effects Oxaliplatin - therapeutic use Pancreatic Neoplasms Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - pathology Treatment Outcome |
| title | Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T10%3A53%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Folfirinox%20versus%20gemcitabine-cisplatin%20combination%20as%20first-line%20therapy%20in%20treatment%20of%20pancreaticobiliary%20cancer&rft.jtitle=TURKISH%20JOURNAL%20OF%20MEDICAL%20SCIENCES&rft.au=Kayahan,%20Neslihan&rft.date=2021-08-30&rft.volume=51&rft.issue=4&rft.spage=1727&rft.epage=1732&rft.pages=1727-1732&rft.issn=1303-6165&rft.eissn=1303-6165&rft_id=info:doi/10.3906/sag-2009-115&rft_dat=%3Cpubmed_cross%3E33315355%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/33315355&rfr_iscdi=true |